A3 adenoside receptor agonists for the reduction of intraocular pressure
AssigneeCan-Fite Biopharma Ltd.
InventorsPnina Fishman, Mordechai Farbstein
Life of this patent
Estimating the term…
Abstract
The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A3R agonist.
Claims13
A method for reducing intraocular pressure (IOP) in a subject comprising administrating to the subject an amount of A3 adenosine receptor (A3AR) agonist, the amount being effective to reduce IOP.
A method for reducing intraocular pressure (IOP) comprising administering to a subject having elevated IOP an amount of IB-MECA, the amount being effective to reduce IOP.
Dependencies are inferred from the claim text.